Inhaled treprostinil: a therapeutic review

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary arterial hypertension (PAH) is a severe condition leading to right ventricular failure.
• Effective PAH therapies include endothelin receptor antagonists, PDE-5 inhibitors, and prostacyclin analogs.
• Treprostinil, a prostacyclin analog, is now available via inhalation.

Purpose of the Study:

• To evaluate the efficacy and safety of inhaled treprostinil in PAH patients.
• To assess the impact of inhaled treprostinil on exercise capacity and other clinical endpoints.
• To determine optimal dosing and patient populations for inhaled treprostinil therapy.

Main Methods:

• The pivotal Phase III TRIUMPH-I trial assessed inhaled treprostinil (54 μg QID) added to background therapy (bosentan or sildenafil).
• Primary endpoint was the change in 6-minute walk distance (6MWD).
• Secondary endpoints included clinical and hemodynamic parameters and safety assessments.

Main Results:

• Inhaled treprostinil demonstrated a median placebo-corrected 20 m improvement in 6MWD.
• The treatment showed a satisfactory safety profile in PAH patients.
• Effectiveness was established in patients with WHO Group I PAH, predominantly NYHA class III.

Conclusions:

• Inhaled treprostinil is an effective and safe therapy for improving exercise ability in PAH patients.
• It is approved for WHO Group I PAH patients to enhance functional capacity.
• The study included patients with idiopathic, heritable, and connective tissue disease-associated PAH.